Lactulose vs Polyethylene Glycol 3350-Electrolyte Solution for Treatment of Overt Hepatic Encephalopathy: The HELP Randomized Clinical Trial | Hepatobiliary Disease | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
Ferenci  P, Lockwood  A, Mullen  K, Tarter  R, Weissenborn  K, Blei  AT.  Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.  Hepatology. 2002;35(3):716-721.PubMedGoogle ScholarCrossref
2.
Blei  AT, Córdoba  J; Practice Parameters Committee of the American College of Gastroenterology.  Hepatic encephalopathy.  Am J Gastroenterol. 2001;96(7):1968-1976.PubMedGoogle ScholarCrossref
3.
Als-Nielsen  B, Gluud  LL, Gluud  C.  Nonabsorbable disaccharides for hepatic encephalopathy.  Cochrane Database Syst Rev. 2004;(2):CD003044.PubMedGoogle Scholar
4.
Elkington  SG, Floch  MH, Conn  HO.  Lactulose in the treatment of chronic portal-systemic encephalopathy: a double-blind clinical trial.  N Engl J Med. 1969;281(8):408-412.PubMedGoogle ScholarCrossref
5.
Bircher  J, Müller  J, Guggenheim  P, Haemmerli  UP.  Treatment of chronic portal-systemic encephalopathy with lactulose.  Lancet. 1966;1(7443):890-892.PubMedGoogle Scholar
6.
van Leeuwen  PA, van Berlo  CL, Soeters  PB.  New mode of action for lactulose.  Lancet.1988;1(8575-6):55-56.PubMedGoogle ScholarCrossref
7.
Dawson  AM, Sherlock  S, Summerskill  WH.  The treatment and prognosis of hepatic coma.  Lancet. 1956;271(6945):689-694.PubMedGoogle Scholar
8.
Manning  RT, Delp  M.  Management of hepatocerebral intoxication.  N Engl J Med. 1958;258(2):55-62.PubMedGoogle ScholarCrossref
9.
Stormont  JM, Mackie  JE, Davidson  CS.  Observations on antibiotics in the treatment of hepatic coma and on factors contributing to prognosis.  N Engl J Med. 1958;259(24):1145-1150.PubMedGoogle ScholarCrossref
10.
Lee  WM, Stravitz  RT, Larson  AM.  Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011.  Hepatology. 2012;55(3):965-967.PubMedGoogle ScholarCrossref
11.
Rahimi  RS, Elliott  AC, Rockey  DC.  Altered mental status in cirrhosis: etiologies and outcomes.  J Investig Med. 2013;61(4):695-700.PubMedGoogle Scholar
12.
Rahimi  RS, Rockey  DC.  Complications and outcomes in chronic liver disease.  Curr Opin Gastroenterol. 2011;27(3):204-209.PubMedGoogle ScholarCrossref
13.
Colli  A, Fraquelli  M, Andreoletti  M, Marino  B, Zuccoli  E, Conte  D.  Severe liver fibrosis or cirrhosis: accuracy of US for detection—analysis of 300 cases.  Radiology. 2003;227(1):89-94.PubMedGoogle ScholarCrossref
14.
Hassanein  T, Blei  AT, Perry  W,  et al.  Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy.  Am J Gastroenterol. 2009;104(6):1392-1400.PubMedGoogle ScholarCrossref
15.
Child  CG, Turcotte  JG. Surgery and portal hypertension. In: Child  CG, ed.  The Liver and Portal Hypertension. Philadelphia, PA: Saunders; 1964:50-64.
16.
Pugh  RN, Murray-Lyon  IM, Dawson  JL, Pietroni  MC, Williams  R.  Transection of the oesophagus for bleeding oesophageal varices.  Br J Surg. 1973;60(8):646-649.PubMedGoogle ScholarCrossref
17.
UNOS. MELD/PELD Calculator Documentation. http://www.unos.org/docs/MELD_PELD_Calculator_Documentation.pdf.2009.
18.
Montgomery  JY, Bajaj  JS.  Advances in the evaluation and management of minimal hepatic encephalopathy.  Curr Gastroenterol Rep. 2011;13(1):26-33.PubMedGoogle ScholarCrossref
19.
Butterworth  RF.  Hepatic encephalopathy: a central neuroinflammatory disorder?  Hepatology. 2011;53(4):1372-1376.PubMedGoogle ScholarCrossref
20.
Jones  EA, Mullen  KD.  Theories of the pathogenesis of hepatic encephalopathy.  Clin Liver Dis. 2012;16(1):7-26.PubMedGoogle ScholarCrossref
21.
Gluud  LL, Dam  G, Borre  M,  et al.  Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?  Metab Brain Dis. 2013;28(2):221-225.PubMedGoogle ScholarCrossref
22.
Eltawil  KM, Laryea  M, Peltekian  K, Molinari  M.  Rifaximin vs conventional oral therapy for hepatic encephalopathy: a meta-analysis.  World J Gastroenterol. 2012;18(8):767-777.PubMedGoogle ScholarCrossref
23.
Hammer  HF, Santa Ana  CA, Schiller  LR, Fordtran  JS.  Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose.  J Clin Invest. 1989;84(4):1056-1062.PubMedGoogle ScholarCrossref
24.
Hammer  HF, Fine  KD, Santa Ana  CA, Porter  JL, Schiller  LR, Fordtran  JS.  Carbohydrate malabsorption: its measurement and its contribution to diarrhea.  J Clin Invest. 1990;86(6):1936-1944.PubMedGoogle ScholarCrossref
25.
Wexner  SD, Beck  DE, Baron  TH,  et al; American Society of Colon and Rectal Surgeons (ASCRS); American Society for Gastrointestinal Endoscopy (ASGE); Society of American Gastrointestinal and Endoscopic Surgeons (SAGES).  A consensus document on bowel preparation before colonoscopy: prepared by a Task Force from the American Society of Colon and Rectal Surgeons (ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES).  Surg Endosc. 2006;20(7):1161.PubMedGoogle ScholarCrossref
26.
US Department of Health and Human Services. Healthcare Cost and Utilization Project (HCUP). http://www.ahrq.gov/research/data/hcup/index.html. Accessed August 1, 2014.
Original Investigation
November 2014

Lactulose vs Polyethylene Glycol 3350-Electrolyte Solution for Treatment of Overt Hepatic Encephalopathy: The HELP Randomized Clinical Trial

Author Affiliations
  • 1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas
  • 2Parkland Memorial Hospital, Parkland Health and Hospital System, Dallas, Texas
  • 3Now with Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, Texas
  • 4Department of Clinical Science, University of Texas Southwestern Medical Center, Dallas
  • 5Now with Department of Internal Medicine, Medical University of South Carolina, Charleston, South Carolina
JAMA Intern Med. 2014;174(11):1727-1733. doi:10.1001/jamainternmed.2014.4746
Abstract

Importance  Hepatic encephalopathy (HE) is a common cause of hospitalization in patients with cirrhosis. Pharmacologic treatment for acute (overt) HE has remained the same for decades.

Objective  To compare polyethylene glycol 3350–electrolyte solution (PEG) and lactulose treatments in patients with cirrhosis admitted to the hospital for HE. We hypothesized that rapid catharsis of the gut using PEG may resolve HE more effectively than lactulose.

Design, Setting, and Participants  The HELP (Hepatic Encephalopathy: Lactulose vs Polyethylene Glycol 3350-Electrolyte Solution) study is a randomized clinical trial in an academic tertiary hospital of 50 patients with cirrhosis (of 186 screened) admitted for HE.

Interventions  Participants were block randomized to receive treatment with PEG, 4-L dose (n = 25), or standard-of-care lactulose (n = 25) during hospitalization.

Main Outcomes and Measures  The primary end point was an improvement of 1 or more in HE grade at 24 hours, determined using the hepatic encephalopathy scoring algorithm (HESA), ranging from 0 (normal clinical and neuropsychological assessments) to 4 (coma). Secondary outcomes included time to HE resolution and overall length of stay.

Results  A total of 25 patients were randomized to each treatment arm. Baseline clinical features at admission were similar in the groups. Thirteen of 25 patients in the standard therapy arm (52%) had an improvement of 1 or more in HESA score, thus meeting the primary outcome measure, compared with 21 of 23 evaluated patients receiving PEG (91%) (P < .01); 1 patient was discharged before final analysis and 1 refused participation. The mean (SD) HESA score at 24 hours for patients receiving standard therapy changed from 2.3 (0.9) to 1.6 (0.9) compared with a change from 2.3 (0.9) to 0.9 (1.0) for the PEG-treated groups (P = .002). The median time for HE resolution was 2 days for standard therapy and 1 day for PEG (P = .01). Adverse events were uncommon, and none was definitely study related.

Conclusions and Relevance  PEG led to more rapid HE resolution than standard therapy, suggesting that PEG may be superior to standard lactulose therapy in patients with cirrhosis hospitalized for acute HE.

Trial Registration  clinicaltrials.gov Identifier: NCT01283152

×